Skip to main content
. 2022 May 31;12:909035. doi: 10.3389/fonc.2022.909035

Figure 4.

Figure 4

The Kaplan-Meier curves of PFS of unresectable or metastatic hepatocellular carcinoma patients in the efficacy-evaluable population stratified by the presence or absence of immune related-adverse events (irAEs) (A), grade 3 treatment-related adverse events (TRAEs) (B), and baseline controlling nutritional status (CONUT) score (> 2 vs. ≤2) (C).